有蹄类动物相关的专利数据

序号	专利名	申请号	申请日	公开（公告）号	公开（公告）日	发明人
101	DETERMINING IMMUNOGLOBULINS IN NON-BLOOD BODY FLUIDS OF NEONATAL UNGULATES	EP09829657.7	2009-11-02	EP2359133A1	2011-08-24	SMITH, Nathan, L.
Provided is a method for determining immunoglobulins in a neonatal ungulate. The method entails obtaining a sample of oral secretions from the neonatal ungulate and measuring an amount of immunoglobulins in the sample of oral secretions. The method is faster and more convenient than previously available methods for determining immunglobulins in neonatal ungulates, such as neonatal horses and cattle.
102	DETERMINING IMMUNOGLOBULINS IN NON-BLOOD BODY FLUIDS OF NEONATAL UNGULATES	EP09829657.7	2009-11-02	EP2359133B1	2013-07-17	SMITH, Nathan, L.

103	DETERMINING IMMUNOGLOBULINS IN NON-BLOOD BODY FLUIDS OF NEONATAL UNGULATES	EP09829657	2009-11-02	EP2359133A4	2012-04-11	SMITH NATHAN L

104	Expression of xenogenous (human) immunoglobulins in cloned, transgenic ungulates	EP08016978.2	2001-11-16	EP2042594B1	2011-03-23	Robl, James M.; Kuroiwa, Yoshimi; Tomizuka, Kazuma; Ishida, Isao

105	TRANSGENIC UNGULATES HAVING REDUCED PRION PROTEIN ACTIVITY AND USES THEREOF	EP03783271	2003-11-10	EP1563084A4	2006-03-01	ROBL JAMES; KUROIWA YOSHIMI; COLLAS PHILIPPE; SULLIVAN EDDIE; KASINATHAN POOTHAPPILLAI; TOMIZUKA KAZUMA; ISHIDA ISAO
The invention provides cloned transgenic ungulates (e.g., bovines) in which prion protein activity is reduced by one or more genetically engineered mutations. Desirably, these transgenic bovines are also genetically modified to express xenogenous (e.g., human) antibodies. Because of their resistance to prion-related diseases such as bovine spongiform encephalopy (also known as mad cow disease), these bovines are a safer source of human antibodies for pharmaceutical uses and safer source of agricultural products.
106	ENRICHED PAG-55-60 FRACTION AND METHODS FOR EARLY DETECTION OF PREGNANCY IN UNGULATE ANIMALS	EP05856658.9	2005-04-27	EP1756584B1	2012-08-01	MATHIALAGAN, Nagappan; MCGRATH, Michael; SCHENKEL, Robert
Disclosed are methods for determining the pregnancy status of an ungulate animal by detecting the level of PAG-55 protein fraction. These methods may involve the detection of PAG-55 enriched proteins in the PAG-55 protein fraction by using novel polyclonal and monoclonal antibodies that have been generated using the PAG-55 enriched protein fraction as an immu1ogen. The novel PAG-55 protein fraction indicates that the animal is pregnant when the acidic PAG-55 protein fraction, or antigenic components thereof, are present at an elevated level in a sample. The present invention also provides for methods of obtaining the PAG-55 enriched protein fraction. The invention provides accurate methods of detecting pregnancy at early stages and has the benefit of allowing early post partum detection of the pregnancy status with fewl false positive results. The antibodies for detecting PAG-55 proteins will also be useful in combination with detecting elevated progesterone levels in the animal, thus providing an even more effective pregnancy detection method. The benefit of this early pregnancy detection is that identifying animals that are not pregnant very shortly after breeding, allows for timely rebreeding and minimizes the amount of time the animal is open. Also disclosed are methods for making a breeding decision for an animal. These methods allow a herd manager to make breeding decisions based on the levels of PAG-55 protein fraction and optionally, progesterone levels detected in a biological sample taken from an animal suspected of being in the early stages of pregnancy.
107	Cloned ungulate embryos and animals, use of cells, tissues and organs thereof for transplantation therapies including Parkinson's disease	US12896396	2010-10-01	US20120076761A1	2012-03-29	Steven Stice; Jose Cibelli; James Robl; Paul Golueke; F. Abel Ponce De Leon; D. Joseph Jerry
Methods and cell lines for cloning ungulate embryos and offspring, in particular bovines and porcines, are provided. The resultant fetuses, embryos or offspring are especially useful for the expression of desired heterologous DNAs, and may be used as a source of cells or tissue for transplantation therapy for the treatment of diseases such as Parkinson's disease.
108	Cloned ungulate embryos and animals, use of cells, tissues and organs thereof for transplantation therapies including parkinson's disease	US11529720	2006-09-26	US20090092588A1	2009-04-09	Steven Stice; Jose Cibelli; James Robl; Paul Golueke; F. Abel Ponce De Leon; D. Joseph Jerry
Methods and cell lines for cloning ungulate embryos and offspring, in particular bovines and porcines, are provided. The resultant fetuses, embryos or offspring are especially useful for the expression of desired heterologous DNAs, and may be used as a source of cells or tissue for transplantation therapy for the treatment of diseases such as Parkinson's disease.
109	Cloned ungulate embryos and animals, use of cells, tissues and organs thereof for transplantation therapies including Parkinson's disease	US10818486	2004-04-05	US20050074439A1	2005-04-07	Steven Stice; Jose Cibelli; James Robl
Methods and cell lines for cloning ungulate embryos and offspring, in particular bovines and porcines, are provided. The resultant fetuses, embryos or offspring are especially useful for the expression of desired heterologous DNAs, and may be used as a source of cells or tissue for transplantation therapy for the treatment of diseases such as Parkinson's disease.
110	Cloned ungulate embryos and animals, use of cells, tissues and organs thereof for transplantation therapies including Parkinson's disease	US09534500	2000-03-24	US20020073439A1	2002-06-13	Steven L. Stice; Jose Cibelli; James M. Robl
Methods and cell lines for cloning ungulate embryos and offspring, in particular bovines and porcines, are provided. The resultant fetuses, embryos or offspring are especially useful for the expression of desired heterologous DNAs, and may be used as a source of cells or tissue for transplantation therapy for the treatment of diseases such as Parkinson's disease.
111	Cloned ungulate embryos and animals, use of cells tissues and organs thereof for transplantation therapies including parkinson's disease	US10260020	2003-03-21	US20040120934A1	2004-06-24	Steven Stice; Jose Cibelli; James M. Robl; Paul Golueke; F. Abel Ponce de Leon; D. Joseph Jerry
Methods and cell lines for cloning ungulate embryos and offspring, in particular bovines and porcines, are provided. The resultant fetuses, embryos or offspring are especially useful for the expression of desired heterologous DNAs, and may be used as a source of cells or tissue for transplantation therapy for the treatment of diseases such as Parkinson's disease.
112	ENRICHED PAG-55 FRACTION AND METHODS FOR EARLY DETECTION OF PREGNANCY IN UNGULATE ANIMALS	EP05856658.9	2005-04-27	EP1756584A2	2007-02-28	MATHIALAGAN, Nagappan; MCGRATH, Michael; SCHENKEL, Robert
Disclosed are methods for determining the pregnancy status of an ungulate animal by detecting the level of PAG-55 protein fraction. These methods may involve the detection of PAG-55 enriched proteins in the PAG-55 protein fraction by using novel polyclonal and monoclonal antibodies that have been generated using the PAG-55 enriched protein fraction as an immu1ogen. The novel PAG-55 protein fraction indicates that the animal is pregnant when the acidic PAG-55 protein fraction, or antigenic components thereof, are present at an elevated level in a sample. The present invention also provides for methods of obtaining the PAG-55 enriched protein fraction. The invention provides accurate methods of detecting pregnancy at early stages and has the benefit of allowing early post partum detection of the pregnancy status with fewl false positive results. The antibodies for detecting PAG-55 proteins will also be useful in combination with detecting elevated progesterone levels in the animal, thus providing an even more effective pregnancy detection method. The benefit of this early pregnancy detection is that identifying animals that are not pregnant very shortly after breeding, allows for timely rebreeding and minimizes the amount of time the animal is open. Also disclosed are methods for making a breeding decision for an animal. These methods allow a herd manager to make breeding decisions based on the levels of PAG-55 protein fraction and optionally, progesterone levels detected in a biological sample taken from an animal suspected of being in the early stages of pregnancy.
113	TRANSGENIC UNGULATES HAVING REDUCED PRION PROTEIN ACTIVITY AND USES THEREOF	EP03783271.4	2003-11-10	EP1563084A2	2005-08-17	ROBL, James; KUROIWA, Yoshimi; COLLAS, Philippe; SULLIVAN, Eddie; KASINATHAN, Poothappillai; TOMIZUKA, Kazuma401, RM2 Takasaki; ISHIDA, Isao352-6 Kushihashi
The invention provides cloned transgenic ungulates (e.g., bovines) in which prion protein activity is reduced by one or more genetically engineered mutations. Desirably, these transgenic bovines are also genetically modified to express xenogenous (e.g., human) antibodies. Because of their resistance to prion-related diseases such as bovine spongiform encephalopy (also known as mad cow disease), these bovines are a safer source of human antibodies for pharmaceutical uses and safer source of agricultural products.
114	EXPRESSION OF XENOGENOUS (HUMAN) IMMUNOGLOBULINS IN CLONED, TRANSGENIC UNGULATES	EP01273248	2001-11-16	EP1343880A4	2005-03-16	ROBL JAMES M; GOLDSBY RICHARD A; FERGUSON STACY E; KUROIWA YOSHIMI; TOMIZUKA KAZUMA; ISHIDA ISAO; OSBORNE BARBARA A
The present invention relates to the production of a trangenic bovine which comprises a genetic modification that resulrs in inactivation and loss of expression of its endogenous antibodies, and the expression of xenogenous antibodies, preferably human antibodies. This is effected by inactivation of the IgM heavy chain expression and, optionally, by inactivation of the Ig light chain expression, and by the further introduction of an artificial chromosome which results on the expression of non-bovine antibodies, preferably human antibodies.
115	Cloned ungulate embryos and animals, use of cells, tissues and organs thereof for transplantation therapies including parkinson's disease	US09845352	2001-05-01	US20010039667A1	2001-11-08	Steven L. Stice; Jose Cibelli; James M. Robl
Methods and cell lines for cloning ungulate embryos and offspring, in particular bovines and porcines, are provided. The resultant fetuses, embryos or offspring are especially useful for the expression of desired heterologous DNAs, and may be used as a source of cells or tissue for transplantation therapy for the treatment of diseases such as Parkinson's disease.
116	Cloned ungulate embryos and animals, use of cells, tissues and organs thereof for transplantation therapies including parkinson's disease	US10809556	2004-03-25	US20040180041A1	2004-09-16	Steven L. Stice; Jose Cibelli; James M. Robl
Methods and cell lines for cloning ungulate embryos and offspring, in particular bovines and porcines, are provided. The resultant fetuses, embryos or offspring are especially useful for the expression of desired heterologous DNAs, and may be used as a source of cells or tissue for transplantation therapy for the treatment of diseases such as Parkinson's disease.
117	Embryonic stem cells as nuclear donors and nuclear transfer techniques to produce chimeric and transgenic animals	EP01115354.1	1994-12-23	EP1149898A2	2001-10-31	Stice, Steven, L.; Strelchenko, Nick; Betthauser, Jeff; Scott, Brett; Jurgella, Gail
The use of embryonic stem (ES) cells as donor nuclei for nuclear transfer (NT) procedures is provided. The method provides for the production of ES cell derived NT embryos. The use of ES cell derived NT embryos for producing chimeric non-human animals, preferably ungulates is also provided. Additionally, the use of transgenic ES cells as nuclear donors to provide transgenic embryos and transgenic offspring is taught.
118	ungulate EMBRYONIC STEM CELLS AS NUCLEAR DONORS AND NUCLEAR TRANSFER TECHNIQUES TO PRODUCE CHIMERIC AND TRANSGENIC ANIMALS	EP95907932.8	1994-12-23	EP0739412B1	2002-02-27	STICE, Steven L.; STRELCHENKO, Nick; BETTHAUSER, Jeff; SCOTT, Brett; JURGELLA, Gail

119	Monoclonal and polyclonal antibodies to equine albumin and hemoglobin and apparatus and methods using the antibodies in the identification and localization of ulcers and other digestive tract bleeding in equines	EP07253688.1	2007-09-18	EP1927859B1	2011-12-14	Pellegrini, Franklin L.; Carter, Scott D.

120	Monoclonal and polyclonal antibodies to equine albumin and hemoglobin and apparatus and methods using the antibodies in the identification and localization of ulcers and other digestive tract bleeding in equines	EP07253688.1	2007-09-18	EP1927859A1	2008-06-04	Pellegrini, Franklin L.; Carter, Scott D.
A diagnostic and testing apparatus and related methods for the use of the same are disclosed which derive and use antibodies to equine albumin and equine hemoglobin in testing apparatus, kits, and methods for detecting and localizing gastric and colonic ulcers or bleeding in horses. Fecal droppings from a horse to be tested are placed in a container together with a buffered liquid solution and mixed thoroughly, following which several drops of liquid from the container are placed into a test kit. Visual markers in the test kits signify the detection of the indicators equine hemoglobin and equine albumin, which are respectively indicative of the presence of gastric and/or colonic ulcers or bleeding.

1 2 3 4 5 6 7 8 9 10

IPRDB

热门服务

关于我们

友情链接

联系方式